237588 Community-based Addiction Treatment Clinical Trials: HIV Rapid Testing and Counseling in Drug Abuse Treatment Practices

Wednesday, November 2, 2011: 10:51 AM

Lisa R. Metsch, PhD , Dept. of Epidemiology & Public Health, Miller School of Medicine, University of Miami, Miami, FL
Louise Haynes, MSW , Division of Clinical Neuroscience, Medical University of South Carolina, Charleston, SC
Drug abuse is a risk factor for HIV infection, and drug abuse clinics present an opportunity to perform rapid testing to identify early stages of the disease. Ensuring that those at risk know their HIV status is a major prevention strategy, and widespread testing is a major public health goal. The CDC recommends that rapid testing be done in all medical settings. To obviate burden and increase the liklihood of testing adoption, CDC recommends that HIV couseling is not necessary in these situations. Because of the opportunity to intervene in high risk patients is so great in drug abuse (DA) clinics, knowing the best approach to rapid HIV testing in those locations is essential. This trial demonstrated 3 approaches: onsite rapid testing with and without counseling and referral at the DA clinic, or testing off site. The trial enrolled 1,281 subjects in 12 outpatient DA community practices across the USA. The demographics of the enrolled subjects showed a representative mix: 39% were women, 21% African American and 11% Hispanic. Clear distinctions were discerned among the treatment conditions, and the lessons and approaches for drug abuse clinics will be discussed.

Learning Areas:
Clinical medicine applied in public health
Implementation of health education strategies, interventions and programs
Public health or related laws, regulations, standards, or guidelines
Public health or related research

Learning Objectives:
Describe the CDC recommendations for HIV testing in medical and non-medical settings. Discuss the most effective approach for HIV rapid testing in drug abuse clinics.

Keywords: HIV/AIDS, Public Health Policy

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I was a co-investigator on the study
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.